Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire employment interview that I came away with a bad viewpoint of the company.

Irony of irony, my bad viewpoint of the company has grown steadily, however, the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the know-how as well as connected intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) and the very first new drug program endorsement ($five million), and even royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and multiple indications, it’s this individual treatment and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple delivering presentations and multiple publications.

Can all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself through the very beginning of my interest in this particular company. Judging with the multiples of thousands of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.

CytoDyn is a classic battleground, or some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *